Acute Effects of the Two Alternative Sweeteners D-allulose and Erythritol on Metabolism
NCT ID: NCT04027283
Last Updated: 2020-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
18 participants
INTERVENTIONAL
2019-09-01
2020-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Oral Pre-loads on Subsequent Energy Intake
NCT04713137
Assessments of Metabolic Responses to Acute Oral Administration of Sucrose, Glucose, and Fructose
NCT06799715
Effects of Artificial Sweetener on Gastrointestinal (GI) Peptide Secretion
NCT00978900
Assessment of Reward Responses to Erythritol Using Flavor Preference Learning
NCT05279183
Effects of Oral Xylitol on Subsequent Energy Intake
NCT05671965
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
D-allulose is a sugar substitute with almost zero calories and is naturally occurring in small quantities. Apart from its use as sugar replacement, D-allulose seems to favorably affect glycemic control and metabolism as could be shown in animal trials and in a few human trials. However, to date the effects of D-allulose on GI hormone secretion, appetite-related sensations and glycemic control, are not or insufficiently studied in humans.
The aim of this project is therefore to investigate the effect of intragastric (ig) D-allulose on metabolic parameters in general and to investigate the effect of sweet taste receptor blockade on GI hormone responses, glycemic control, gastric emptying (GE) rates and appetite-related sensations to ig administration of erythritol and D-allulose.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Erythritol
18 volunteers receive 50g erythritol dissolved in 300mL tap water via a nasogastric tube
Erythritol
50g erythritol dissolved in 300mL tap water
Erythritol + lactisole
18 volunteers receive 50g erythritol with lactisol (450ppm) dissolved in 300mL tap water via a nasogastric tube
Erythritol + lactisole
50g erythritol + lactisole (450ppm) dissolved in 300mL tap water
D-allulose
18 volunteers receive 25g D-allulose dissolved in 300mL tap water via a nasogastric tube
D-allulose
25g D-allulose dissolved in 300mL tap water
D-allulose + lactisole
18 volunteers receive 25g D-allulose with lactisole (450ppm) dissolved in 300mL tap water via a nasogastric tube
D-allulose + lactisole
25g D-allulose + lactisole (450ppm) dissolved in 300mL tap water
Tap water
18 volunteers receive 300mL tap water via a nasogastric tube
Tap water
300mL tap water
Tap water + lactisole
18 volunteers receive 300mL tap water + lactisole (450ppm) via a nasogastric tube
Tap water + lactisole
300mL tap water + lactisole (450ppm)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Erythritol
50g erythritol dissolved in 300mL tap water
Erythritol + lactisole
50g erythritol + lactisole (450ppm) dissolved in 300mL tap water
D-allulose
25g D-allulose dissolved in 300mL tap water
D-allulose + lactisole
25g D-allulose + lactisole (450ppm) dissolved in 300mL tap water
Tap water
300mL tap water
Tap water + lactisole
300mL tap water + lactisole (450ppm)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal eating habits (no diets; no dietary changes)
* Age 18-55 years
* Stable body weight for at least three months
* Informed Consent as documented by signature (Appendix Informed Consent Form)
Exclusion Criteria
* Substance abuse
* Regular intake of medications, except anticonceptives
* Chronic or clinically relevant acute infections
* Pregnancy: although no contraindication, pregnancy might influence metabolic state. Women who are pregnant or have the intention to become pregnant during the course of the study are excluded. In female participants a urine pregnancy test is carried out upon screening.
* Participation in another study with investigational drug within the 30 days preceding and during the present study.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Basel, Switzerland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne Christin Meyer-Gerspach, PD, PhD
Role: PRINCIPAL_INVESTIGATOR
St. Clara Research Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Claraspital
Basel, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PolyAlluLac
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.